默沙东 MRK 深 沪
已收盘 08-07 16:00:00 美东时间
128.58
+0.210
+0.16%
华盛通- 最 高128.75
- 今 开127.84
- 成交量 734.76万股
- 最 低 126.68
- 昨 收 128.37
- 总市值 3175.70亿
- 52周最高 135.05
- 市盈率 静 17.66
- 换手率 0.30%
- 52周最低 75.03
- 委 比 76.47%
- 总股本 24.70亿
- 历史最高 135.05
- 量 比 0.76
- 振 幅 1.61%
- 历史最低 -5.356
- 每 手 1
- 风险率 16.70%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多财报速睇 | 默沙东 2026财年Q2营收166.07亿美元，同比增长5.1%；归母净利润亏损13.35亿美元，由盈转亏
华盛资讯8月8日讯，默沙东公布2026财年Q2业绩，公司Q2营收166.07亿美元，同比增长5.1%，归母净利润亏损13.35亿美元，由盈转亏。
08-08 07:03
默沙东(MRK.US)抗艾滋病口服新药在中国申报上市
8月5日，中国国家药监局药品审评中心(CDE)官网公示显示，默沙东(MRK.US)申报的多拉韦林伊拉曲韦片(doravirine/islatravir，DOR...
08-06 21:10
生命科学与电子业务双轮驱动，德国默克Q2超预期并上调全年盈利指引
得益于其实验室设备与电子业务表现走强，德国默克集团（Merck KGaA）周四发布超预期的第二季度财报，并上调全年盈利及销售指引。
08-06 14:25
美股大行评级 | AMD、Arista Networks、Booking 、加特纳、Pinterest、科力斯、Wayfair等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Precigen"买入"评级，目标价从14美元升至18美元；HC Wainwright & Co.：维持Sophia Genetics"买入"评级，目标价从12美元升至14美元
08-06 11:36
“造雨人”药明康德
本文系基于公开资料撰写，仅作为信息交流之用，不构成任何投资建议 希腊神话里，普罗米修斯从奥林匹斯山盗取火种，赠予人间。火种降世之前，火是神明的特权，人间只...
08-06 12:30
Merck's KEYTRUDA Plus Enfortumab Vedotin Approved In Canada For Cisplatin-Ineligible Muscle-Invasive Bladder Cancer Patients
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced that KEYTRUDA® (pembrolizumab for injection), Merck's anti-PD-1 therapy, in combination with enfortumab vedotin, an antibody-drug conjugate (ADC), is approved by Health Canada as neoadjuvant treatment and then continue...
08-05 23:01
Guggenheim Maintains Buy on Merck & Co, Raises Price Target to $146
Guggenheim analyst Vamil Divan maintains Merck & Co (NYSE:MRK) with a Buy and raises the price target from $145 to $146.
08-05 20:21
从默沙东告别“单一Keytruda神药”时代到中国创新药崛起 新一轮医药投资浪潮席卷全球
美国医药巨头默沙东(MRK.US)首席执行官罗伯·戴维斯周二接受媒体采访时表示，这家制药巨头的未来增长前景已不再仅仅依赖重磅癌症疗法Keytruda。随着“药王...
08-05 15:21
公司简介
公司名称
|
默沙东
|
行业分类
|
制药
|
业务描述
|
默沙东公司是世界级跨国医药企业领导者，着手解决社会对医疗健康上的需要。默沙东提供创新的药物、疫苗、生物制剂及健康消费品以及动物健康产品，以改善及提升健康质素。默沙东现时已于全球140个不同地方为消费者提供医疗健康解决方案。同时藉由深入各地区角落的医疗计划，提供药品给需要的人们，以解决偏远地区医疗不足的情况。默沙东在美国及加拿大内称为默克药厂（Merck & Co., Inc.），在其他不同地区则以默沙东药厂(Merck Sharp & Dohme，MSD)为名。
|
财报速睇 | 默沙东 2026财年Q2营收166.07亿美元，同比增长5.1%；归母净利润亏损13.35亿美元，由盈转亏
华盛资讯8月8日讯，默沙东公布2026财年Q2业绩，公司Q2营收166.07亿美元，同比增长5.1%，归母净利润亏损13.35亿美元，由盈转亏。
08-08 07:03
默沙东(MRK.US)抗艾滋病口服新药在中国申报上市
8月5日，中国国家药监局药品审评中心(CDE)官网公示显示，默沙东(MRK.US)申报的多拉韦林伊拉曲韦片(doravirine/islatravir，DOR...
08-06 21:10
生命科学与电子业务双轮驱动，德国默克Q2超预期并上调全年盈利指引
得益于其实验室设备与电子业务表现走强，德国默克集团（Merck KGaA）周四发布超预期的第二季度财报，并上调全年盈利及销售指引。
08-06 14:25
美股大行评级 | AMD、Arista Networks、Booking 、加特纳、Pinterest、科力斯、Wayfair等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Precigen"买入"评级，目标价从14美元升至18美元；HC Wainwright & Co.：维持Sophia Genetics"买入"评级，目标价从12美元升至14美元
08-06 11:36
“造雨人”药明康德
本文系基于公开资料撰写，仅作为信息交流之用，不构成任何投资建议 希腊神话里，普罗米修斯从奥林匹斯山盗取火种，赠予人间。火种降世之前，火是神明的特权，人间只...
08-06 12:30
Merck's KEYTRUDA Plus Enfortumab Vedotin Approved In Canada For Cisplatin-Ineligible Muscle-Invasive Bladder Cancer Patients
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced that KEYTRUDA® (pembrolizumab for injection), Merck's anti-PD-1 therapy, in combination with enfortumab vedotin, an antibody-drug conjugate (ADC), is approved by Health Canada as neoadjuvant treatment and then continue...
08-05 23:01
Guggenheim Maintains Buy on Merck & Co, Raises Price Target to $146
Guggenheim analyst Vamil Divan maintains Merck & Co (NYSE:MRK) with a Buy and raises the price target from $145 to $146.
08-05 20:21
从默沙东告别“单一Keytruda神药”时代到中国创新药崛起 新一轮医药投资浪潮席卷全球
美国医药巨头默沙东(MRK.US)首席执行官罗伯·戴维斯周二接受媒体采访时表示，这家制药巨头的未来增长前景已不再仅仅依赖重磅癌症疗法Keytruda。随着“药王...
08-05 15:21
派息除权日
|
每股总股息
| 派息日期 |
2026-09-15
|
0.85
|
2026-10-07
|
2026-06-15
|
0.85
|
2026-07-08
|
2026-03-16
|
0.85
|
2026-04-07
|
2025-12-15
|
0.85
|
2026-01-08
|
2025-09-15
|
0.81
|
2025-10-07
|
2025-06-16
|
0.81
|
2025-07-08
|
2025-03-17
|
0.81
|
2025-04-07
|
2024-12-16
|
0.81
|
2025-01-08
|
2024-09-16
|
0.77
|
2024-10-07
|
2024-06-17
|
0.77
|
2024-07-08
|
2024-03-14
|
0.77
|
2024-04-05
|
2023-12-14
|
0.77
|
2024-01-08
|
2023-09-14
|
0.73
|
2023-10-06
|
2023-06-14
|
0.73
|
2023-07-10
|
2023-03-14
|
0.73
|
2023-04-10
|
2022-12-14
|
0.73
|
2023-01-09
|
2022-09-14
|
0.69
|
2022-10-07
|
2022-06-14
|
0.69
|
2022-07-08
|
2022-03-14
|
0.69
|
2022-04-07
|
2021-12-14
|
0.69
|
2022-01-07
|
2021-09-14
|
0.65
|
2021-10-07
|
2021-06-14
|
0.65
|
2021-07-07
|
2021-03-12
|
0.65
|
2021-04-07
|
2020-12-14
|
0.65
|
2021-01-08
|
2020-09-14
|
0.61
|
2020-10-07
|
2020-06-12
|
0.61
|
2020-07-07
|
2020-03-13
|
0.61
|
2020-04-07
|
2019-12-13
|
0.61
|
2020-01-08
|
2019-09-13
|
0.55
|
2019-10-07
|
2019-06-14
|
0.55
|
2019-07-08
|
2019-03-14
|
0.55
|
2019-04-05
|
2018-12-14
|
0.55
|
2019-01-08
|
2018-09-14
|
0.48
|
2018-10-05
|
2018-06-14
|
0.48
|
2018-07-09
|
2018-03-14
|
0.48
|
2018-04-06
|
2017-12-14
|
0.48
|
2018-01-08
|
2017-09-14
|
0.47
|
2017-10-06
|
2017-06-13
|
0.47
|
2017-07-10
|
2017-03-13
|
0.47
|
2017-04-07
|
2016-12-13
|
0.47
|
2017-01-09
|
2016-09-13
|
0.46
|
2016-10-07
|
2016-06-13
|
0.46
|
2016-07-08
|
2016-03-11
|
0.46
|
2016-04-07
|
2015-12-11
|
0.46
|
2016-01-08
|
2015-09-11
|
0.45
|
2015-10-07
|
2015-06-11
|
0.45
|
2015-07-08
|
2015-03-12
|
0.45
|
2015-04-08
|
2014-12-11
|
0.45
|
2015-01-08
|
2014-09-11
|
0.44
|
2014-10-07
|
2014-06-12
|
0.44
|
2014-07-08
|
2014-03-13
|
0.44
|
2014-04-07
|
2013-12-12
|
0.44
|
2014-01-08
|
2013-09-12
|
0.43
|
2013-10-07
|
2013-06-13
|
0.43
|
2013-07-08
|
2013-03-13
|
0.43
|
2013-04-05
|
2012-12-13
|
0.43
|
2013-01-08
|
2012-09-13
|
0.42
|
2012-10-05
|
2012-06-13
|
0.42
|
2012-07-09
|
2012-03-13
|
0.42
|
2012-04-06
|
2011-12-13
|
0.42
|
2012-01-09
|
2011-09-13
|
0.38
|
2011-10-07
|
2011-06-13
|
0.38
|
2011-07-08
|
2011-03-11
|
0.38
|
2011-04-07
|
2010-12-13
|
0.38
|
2011-01-07
|
2010-09-13
|
0.38
|
2010-10-07
|
2010-06-11
|
0.38
|
2010-07-08
|
2010-03-11
|
0.38
|
2010-04-07
|
2009-12-11
|
0.38
|
2010-01-08
|
2009-09-02
|
0.38
|
2009-10-01
|
2009-06-04
|
0.38
|
2009-07-01
|
2009-03-04
|
0.38
|
2009-04-01
|
2008-12-03
|
0.38
|
2009-01-02
|
2008-09-03
|
0.38
|
2008-10-01
|
2008-06-04
|
0.38
|
2008-07-01
|
2008-03-05
|
0.38
|
2008-04-01
|
2007-12-05
|
0.38
|
2008-01-02
|
2007-09-05
|
0.38
|
2007-10-01
|
2007-06-06
|
0.38
|
2007-07-02
|
2007-03-07
|
0.38
|
2007-04-02
|
2006-12-06
|
0.38
|
2007-01-02
|
2006-08-30
|
0.38
|
2006-10-02
|
2006-05-31
|
0.38
|
2006-07-03
|
2006-03-08
|
0.38
|
2006-04-03
|
2005-11-30
|
0.38
|
2006-01-03
|
2005-08-31
|
0.38
|
2005-10-03
|
2005-06-01
|
0.38
|
2005-07-01
|
2005-03-02
|
0.38
|
2005-04-01
|
2004-12-01
|
0.38
|
2005-01-03
|
2004-09-01
|
0.38
|
2004-10-01
|
2004-06-02
|
0.37
|
2004-07-01
|
2004-03-03
|
0.37
|
2004-04-01
|
2003-12-03
|
0.37
|
2004-01-02
|
2003-09-03
|
0.37
|
2003-10-01
|
2003-06-04
|
0.36
|
2003-07-01
|
2003-03-05
|
0.36
|
2003-04-01
|
2002-12-04
|
0.36
|
2003-01-02
|
2002-09-04
|
0.36
|
2002-10-01
|
2002-06-05
|
0.35
|
2002-07-01
|
2002-03-06
|
0.35
|
2002-04-01
|
2001-12-05
|
0.35
|
2002-01-02
|
2001-08-30
|
0.35
|
2001-10-01
|
2001-05-31
|
0.34
|
2001-07-02
|
2001-03-07
|
0.34
|
2001-04-02
|
2000-12-06
|
0.34
|
2001-01-02
|
2000-08-30
|
0.34
|
2000-10-02
|
2000-05-31
|
0.29
|
2000-07-03
|
2000-03-01
|
0.29
|
2000-04-03
|
1999-12-01
|
0.29
|
2000-01-03
|
1999-09-01
|
0.29
|
1999-10-01
|
1999-06-02
|
0.27
|
1999-07-01
|
1999-03-03
|
0.27
|
1999-04-01
|
1998-12-02
|
0.54
|
1999-01-04
|
1998-09-02
|
0.54
|
1998-10-01
|
1998-06-03
|
0.45
|
1998-07-01
|
1998-03-04
|
0.45
|
1998-04-01
|
1997-12-03
|
0.45
|
1998-01-02
|
1997-09-03
|
0.45
|
1997-10-01
|
1997-06-05
|
0.42
|
1997-07-01
|
1997-03-05
|
0.42
|
1997-04-01
|
1996-12-05
|
0.40
|
1997-01-02
|
1996-09-04
|
0.40
|
1996-10-01
|
1996-06-06
|
0.34
|
1996-07-01
|
1996-03-06
|
0.34
|
1996-04-01
|
1995-12-06
|
0.34
|
1996-01-02
|
1995-09-05
|
0.34
|
1995-10-02
|
1995-06-02
|
0.30
|
1995-07-03
|
1995-03-03
|
0.30
|
1995-04-03
|
1994-12-02
|
0.30
|
1995-01-02
|
1994-09-02
|
0.30
|
1994-10-01
|
1994-06-02
|
0.28
|
1994-07-01
|
1994-03-02
|
0.28
|
1994-04-01
|
1993-12-02
|
0.28
|
1994-01-03
|
1993-09-02
|
0.28
|
1993-10-01
|
1993-06-02
|
0.25
|
1993-07-01
|
1993-03-02
|
0.25
|
1993-04-01
|
1992-12-02
|
0.25
|
1993-01-04
|
1992-08-31
|
0.25
|
1992-10-01
|
1992-06-02
|
0.23
|
1992-07-01
|
1992-03-02
|
0.69
|
1992-04-01
|
1991-12-02
|
0.63
|
1992-01-02
|
1991-08-30
|
0.63
|
1991-10-01
|
1991-06-03
|
0.56
|
1991-07-01
|
1991-03-04
|
0.56
|
1991-04-01
|
1990-12-03
|
0.56
|
1991-01-02
|
1990-08-28
|
0.56
|
1990-10-01
|
1990-05-29
|
0.45
|
1990-07-02
|
1990-03-05
|
0.45
|
1990-04-02
|
1989-12-04
|
0.45
|
1990-01-02
|
1989-08-29
|
0.45
|
1989-10-02
|
1989-05-30
|
0.41
|
1989-07-05
|
1989-03-02
|
0.41
|
1989-04-03
|
1988-11-29
|
0.37
|
1989-01-03
|
1988-08-29
|
0.37
|
1988-10-03
|
1988-06-03
|
0.32
|
1988-07-05
|
1988-02-29
|
0.96
|
1988-04-04
|
1987-12-01
|
0.80
|
1988-01-04
|
1987-08-28
|
0.80
|
1987-10-01
|
1987-06-02
|
0.55
|
1987-07-01
|
1987-03-02
|
0.55
|
1987-04-01
|
1986-12-02
|
0.55
|
1987-01-02
|
1986-09-02
|
0.55
|
1986-10-01
|
1986-06-03
|
0.45
|
1986-07-01
|
1986-02-27
|
0.90
|
1986-04-01
|
1985-12-03
|
0.90
|
1986-01-02
|
1985-08-30
|
0.80
|
1985-10-01
|
1985-06-03
|
0.80
|
1985-07-01
|
1985-02-28
|
0.80
|
1985-04-01
|
1984-12-03
|
0.80
|
1985-01-02
|
1984-08-31
|
0.75
|
1984-10-01
|
1984-05-29
|
0.75
|
1984-07-02
|
1984-03-01
|
0.75
|
1984-04-02
|
1983-11-29
|
0.75
|
1984-01-02
|
1983-08-29
|
0.70
|
1983-09-30
|
1983-05-31
|
0.70
|
1983-06-30
|
1983-02-28
|
0.70
|
1983-04-01
|
1982-11-30
|
0.70
|
1983-01-03
|
1982-08-30
|
0.70
|
1982-10-01
|
1982-06-01
|
0.70
|
1982-07-01
|
1982-03-01
|
0.70
|
1982-04-01
|
1981-12-01
|
0.70
|
1982-01-04
|
1981-08-31
|
0.65
|
1981-10-01
|
1981-06-01
|
0.65
|
1981-07-01
|
1981-03-02
|
0.65
|
1981-04-01
|
1980-12-02
|
0.65
|
1981-01-02
|
1980-08-29
|
0.57
|
1980-10-01
|
1980-06-02
|
0.57
|
1980-07-01
|
1980-02-27
|
0.57
|
1980-03-31
|
1979-12-02
|
0.57
|
1980-01-01
|
1979-08-30
|
0.47
|
1979-09-30
|
1979-05-24
|
0.47
|
1979-07-01
|
1979-02-28
|
0.47
|
1979-04-01
|
1978-12-03
|
0.47
|
1979-01-01
|
1978-08-27
|
0.43
|
1978-10-01
|
1978-05-25
|
0.43
|
1978-06-30
|
1978-03-01
|
0.43
|
1978-03-31
|
1977-11-27
|
0.43
|
1978-01-01
|
1977-08-28
|
0.38
|
1977-09-30
|
1977-05-30
|
0.38
|
1977-06-30
|
1977-02-28
|
0.38
|
1977-03-31
|
